IDEAYA Biosciences, Inc. (IDYA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 82.68M USD | Liabilities, Current |
| Cash and equivalents | 272.59M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 556.37M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $82.68M | $272.59M | $556.37M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $64.83M | $157.52M | $513.68M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $58.81M | $112.83M | $526.56M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $64.51M | $298.93M | $487.97M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $55.34M | $114.64M | $555.09M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $50.85M | $130.00M | $562.51M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $46.07M | $84.38M | $591.94M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $40.66M | $400.28M | $519.75M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $40.74M | $183.05M | $518.61M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $24.96M | $108.34M | $590.43M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $27.10M | $157.02M | $368.10M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $24.89M | $151.85M | $316.90M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $25.34M | $102.84M | $390.87M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $29.82M | $67.24M | $272.23M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $31.72M | $68.63M | $296.20M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $32.73M | $101.95M | $284.29M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $58.09M | $49.11M | $219.51M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $56.96M | $55.29M | $197.31M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $45.16M | $92.05M | $154.72M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $38.64M | $108.43M | $156.12M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $35.77M | $90.43M | $183.75M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $36.13M | $136.75M | $165.57M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $38.64M | $72.04M | $211.55M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $54.17M | $81.24M | $197.44M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $7.43M | $147.54M | $22.87M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $7.35M | $35.46M | $52.40M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $6.94M | $34.07M | $64.89M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $5.95M | $38.85M | $70.51M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $6.47M | $88.11M | $32.05M | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $35.30M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $5.41M | $20.50M | $69.46M | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $21.48M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $24.87M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $5.96M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |